The patient was diagnosed with group D COPD in 2009 (mMRC score of 4, COPD assessment test score of 26, and multiple moderate exacerbations): He claimed that he stopped for breath after a few minutes of walking, had a chronic cough that was occasionally productive, often felt chest tightness, felt breathless after trying to walk up a hill, was limiting doing activities at home, was not so confident leaving his house knowing his lung condition, did not always sleep soundly, and has limited energy. A 7-year clinical follow-up after stem cell therapy for the patient in our case revealed a decrease in major symptoms and oxygen requirement, notably during the first 5 years following therapy.Ī 67-year-old man presented as an outpatient in 2015 for a trial of stem cell therapy for COPD. This technique uses partially differentiated and specifically redirected Autologous Bone Marrow Mononuclear Stem Cells (BM-MSCs) (trademark ID number: 168469). We report the case of a 74-year-old patient diagnosed with group D COPD for more than 13 years who underwent stem cell therapy with the Regentime® procedure. MSCs have progenitor and immune-regulatory properties that implicated them in the potential clinical application in treating immune-based diseases such as COPD. Due to the absence of a curative therapeutic option that prevents disease progression, the treatment of COPD using mononuclear stem cells has been suggested. The estimated 4-year survival ranges from 18 to 80% depending on the patient's BODE score (the higher the index, the worse the condition). It is based on FEV1 (forced expiratory volume in the first second), 6-minute walking distance, mMRC (modified medical research council) dyspnea scale, and body mass index. The 4-year survival rate of COPD patients can be predicted using a unique scoring system, the BODE index. COPD patients typically present with progressive dyspnea, cough, and sputum production. The release of multiple inflammatory mediators, oxidants, and excess proteases leads to alveolar sacs destruction with a subsequent loss of elastic recoil and obstructive physiology. The pathophysiology of COPD involves oxidative stress and protease/antiprotease imbalance affecting the airways, lung parenchyma, and pulmonary vasculature. It is caused by prolonged exposure to harmful particles, notably cigarette smoke, leading to chronic inflammation and structural lung changes. Regentime® procedure, Bone marrow-mesenchymal stem cells, Chronic obstructive pulmonary diseaseĬhronic Obstructive Pulmonary Disease (COPD) is the third most common cause of morbidity and mortality worldwide, characterized by persistent airflow limitation and tissue destruction. The results obtained support stem cell-based therapy as a promising therapeutic option for patients suffering from COPD. However, regression was registered during the past 2 years during which the patient's oxygen requirement increased for optimal oxygen saturation. Clinical follow-up 5 years after transplantation showed a decrease in major symptoms, including dyspnea, cough, fatigue, and decreased oxygen requirement. This technique uses Autologous Bone Marrow -Mononuclear Stem Cells (BM-MSCs) which are partially differentiated and specifically redirected to the desired organ. We present the case of a 74-year-old gentleman diagnosed with COPD who underwent stem cell therapy with the Regentime® Procedure. Despite the advance in therapeutic approaches, no curative clinical treatment for COPD exists. It is characterized by airway and parenchymal inflammation leading to airway narrowing, decreased lung recoil, and eventual airflow limitation. The hypothesized outcomes of therapy are safety and minimization of adverse events, a perceived improvement in the patient's lung condition (to be determined by their perceived quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce supplemental oxygen use, the ability to function well without the use of rescue inhalers, reduction of secondary pulmonary infections, reduction in emergency room visits and exacerbations related to their disease.Chronic Obstructive Pulmonary Disease (COPD) is a common disease associated with high morbidity and mortality rates. The patient's cells and platelet rich plasma are harvested through venous or bone marrow collection techniques. Lung Institute's treatment is limited to self-funded patients with chronic lung disease- chronic obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis (PF) and interstitial lung disease (ILD). The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day. Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |